Parainfluenza vaccine

Paraformaldehyde, 2 623 22 123 Paraformaldehyde solids, 22 119 para-hydrogen, 23 759, 760—761, 764 vapor pressure of, 23 764 Parainfluenza vaccine, 25 498 Paraldehyde, 2 103 Parallax errors, in liquid-in-glass thermometers, 24 465 Parallel-counterflow exchanger, heat-exchanger effectiveness for, 23 255 Parallel flow heat exchangers heat-exchanger effectiveness for,... 

Parainfluenza. Parainfluenza vimses (PIV) also causes viral pneumonia in infants. It is similar to RSV, therefore similar approaches are being used for developing a vaccine. A five attenuated PIV-3 vaccine has been in clinical trial (74). 

Brideau, R.J. Oien, N.L. Lehman, D.J. Homa, F.L. Wathen, M.W. Protection of cotton rats against human parainfluenza virus type 3 by vaccination with a chimeric FHN subunit glycoprotein. J. Gen. Virol. 1993, 74, 471-477. 

Chin J, Magoffin RL, Shearer LA, Schieble JH, Lenette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969 89 449-463. 

Whereas AIDS andHIV was only chosen as examples that contributes any imaginable difficulty to vaccine development. Table 2 also lists many other current vaccine projects and their specific difficulties. A limited number of different serotypes may still be overcome by making and combining several similar vaccines, once a successful vaccine against one of these has been accomplished. Thus, vaccines against parainfluenza infections appear reasonably feasible. Other indications, such as malaria, herpesvirus infections or Lyme... 

---